SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Art Pappas will speak at the Drug Repositioning Summit on October 6 in Boston, MA
News | 10. 06. 2008
